Orphacol (Cholic Acid)

Cholic acid supplements the natural bile acid pool. After oral intake it is absorbed, conjugated in the liver and secreted into bile where it activates the farnesoid X receptor (FXR). This activation promotes micelle formation, enhances lipid emulsification, and normalizes feedback control of bile acid synthesis.

The dosage of Orphacol is individualized. A qualified prescriber determines the appropriate amount based on the patient’s age, weight, severity of the bile acid disorder, and clinical response. No fixed dosing regimen is provided in public literature.

Safety data for cholic acid during pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss potential risks and monitor both mother and child closely.

To order Orphacol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The team then replies with pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

The most common alternative for bile acid replacement is ursodeoxycholic acid (UDCA). While UDCA is primarily used for cholestatic liver diseases, cholic acid directly replaces the missing primary bile acid, offering a more physiological restoration of the bile acid pool in genetic synthesis disorders. Choice depends on the specific disorder and physician assessment.

Orphacol should be stored at room temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain stability.

Orphacol is administered orally. The powder is typically reconstituted in water or a suitable liquid as directed by the prescriber and taken with or without food, depending on individual tolerance and therapeutic guidance.

Serious risks include hepatotoxicity, manifested by elevated liver enzymes, and rare hypersensitivity reactions such as anaphylaxis. Pancreatitis has also been reported. Patients should be instructed to seek immediate medical attention if they experience severe abdominal pain, jaundice, rash, swelling, or breathing difficulties.

Orphacol should be avoided in individuals with known hypersensitivity to cholic acid or any excipients in the formulation. It is also contraindicated in patients with active gallstone disease where alteration of bile composition could exacerbate symptoms.